Seven years after the US Food and Drug Administration banned silicone gel breast implants, dispute over their relation to connective tissue diseases continues in courtrooms throughout the United States. The development of mass tort products liability' in the context of medical products has been discussed elsewhere 1 . This article is an update on events surrounding the breast implant controversy and the way expert scienti®c panels have been used to counter what is commonly termed junk science.
From the early 1980s there were reports of connective tissue disease in women with silicone breast implants and several successful lawsuits. However, starting in 1994, a series of well-controlled, well-conducted epidemiological studies failed to reveal any association between silicone gel breast implants and various connective tissue diseases 2±10 . These studies continue to be published and at present number about 26. An objective scienti®c analyst would now be hard pressed to conclude that breast implants are related to connective tissue disease. Nonetheless, lawsuits continue to work their way through the United States court system. These claims are usually decided by lay juries, which tend to be swayed by emotional (as opposed to rational) factors presented to them at trial. Their sympathy for plaintiffs is bolstered by declarations from`experts' who claim to provide a scienti®c basis for cause-and-effect relations. It is dif®cult, if not impossible, for lay jurors to separate good science from junk science, particularly when they have to weigh the results of highly technical scienti®c studies against personal testimonies. Thus, lay juries continue to ®nd for the plaintiffs. For example, on 4 January 1999 a federal jury in Washington, DC, awarded $10 million to a woman who contended that her leaking implants caused her to develop sclerodermaÐdespite evidence from several epidemiological studies of no association. The fallibility of the jury system in litigation involving highly technical scienti®c matters has attracted the attention of various judges in the court system as well as commentators in the medical/ scienti®c community. Lately, the courts involved with the silicone gel breast implant litigation have taken steps to correct this inconsistency.
PANELS APPOINTED BY THE COURTS
We have previously discussed the changing judicial standards in the United States for scienti®c evidence, under the case of Daubert v. Merrell Dow Pharmaceuticals, Inc 1 . The standards laid down by that case require judges to act as gatekeepers' of scienti®c evidence. Pursuant to this role, the judge is required to do a preliminary assessment of the reasoning or methodology underlying proposed scienti®c testimony, to determine whether it is valid and can properly be applied to the facts at issue. Such evidence is to be admitted only if it is founded on the methods and procedures of scienceÐi.e. it is more than subjective belief or unsupported speculation.
As a result of the Daubert mandate, several judges appointed independent scienti®c expert panels to review the disease issues in the silicone gel breast implant litigation and report their conclusions. Judge Robert Jones, of the US District Court in Portland, Oregon, appointed a panel of expert advisors to assist him in analysing the claimed association of breast implants and connective tissue disease. Following extensive hearings and expert testimony the panel reported its conclusions to Judge Jones, who concluded that, since atypical connective tissue disease is at best an untested hypothesis, there is no scienti®c basis for any expert testimony as to its causes and presence in plaintiffs'. As a result, Judge Jones excluded the junk science experts and their theories from the case.
Judge Jack Weinstein, of the US District Court for the Eastern District of New York, after conducting his own hearings and analysing the materials from Judge Jones and his advisors, reached the same conclusion, stating:
The hundreds of symptoms associated with this undifferentiated disease, the lack of any acceptable agreed upon de®nition, the inadequacy of any satisfactory supporting epidemiological or animal studies, the lack of a scienti®cally acceptable showing of medical plausibility, and the questionable nature of the clinical conclusions of the treating doctors, all point to a failure of proof in making a prima facie case that silicone implants cause any of the syndromes claimed . . . ' silicone gel breast implants, Judge Sam Pointer, Chief Judge of the US District Court for the District of Alabama and the judge to whom all federal silicone gel breast implant cases are assigned for pretrial handling, appointed his own scienti®c panel under Rule 706 of the Federal Rules of Civil Procedure. This`Rule 706 National Science Panel' consisted of four experts, on rheumatology, epidemiology, immunology and toxicology, who were charged with determining the extent to which`existing studies, research and reported observations provided reliable and reasonable scienti®c basis for one to conclude that silicone gel breast implants cause or exacerbate . . . ' any one of several conditions outlined by the court. That panel began work in 1996 and for two years exhaustively examined the publications submitted by both plaintiffs and defendants, listened to testimony from expert witnesses chosen by the parties and then invited their own experts to discuss the causation question. While Judge Pointer's science panel was conducting its exhaustive review, several courts, in Texas, Colorado, California, New Mexico, Georgia and other jurisdictions, analysed the scienti®c evidence under the standards of Daubert and struck testimony by plaintiffs' junk science experts. These courts concluded that the lack of any epidemiological studies showing that the plaintiffs' diseases were more likely than not caused by their breast implants was fatal to their cases.
In the absence of epidemiological studies to support their position, the plaintiffs and their hired experts then submitted other types of evidenceÐsuch as animal studies, case reports, reanalysis of the epidemiological studies, blood tests, and temporality claims. These were all found inadequate, particularly where there was con¯icting evidence from epidemiology.
OPINIONS FROM OTHER SCIENTIFIC BODIES
On the scienti®c front, various scienti®c and medical groups examined the issue and reached essentially the same conclusions as the courts and their scienti®c panels. In July 1998, EQUAM (European Committee on Quality Assurance and Medical Devices in Plastic Surgery) issued its consensus declaration on breast implants based on analysis of the existing scienti®c studies. The statement declared that:
There are conclusive scienti®cÐclinical, immunological, epidemiologicalÐdata that silicone gel ®lled breast implants do not cause any autoimmune and/or connective tissue diseases. There is no scienti®c evidence that such things as silicone allergy, silicone intoxication, atypical disease, or a``new silicone disease'' exists. There is a normal foreign body reaction to every implant, but this is not immune disease'. 11 Also, in July, 1998, an Independent Review Group (IRG) appointed by the Chief Medical Of®cer of the UK Department of Health issued comprehensive ®ndings from its analysis of the relation between breast implants and autoimmune disease. That group, which included rheumatologists, immunologists, plastic surgeons, pathologists and toxicologists, stated:
1 There is no histopathological or conclusive immunological evidence for an abnormal immune response to silicone from breast implants in tissue. 2 There is no epidemiological evidence for any link between silicone gel breast implants and any established connective disease. If there is a risk of connective tissue disease, it is too small to be quanti®ed. The IRG cannot justify recommending further epidemiological studies to investigate this hypothesis. 3 Good evidence of the existence of atypical connective tissue disease or unde®ned conditions, such as``silicone poisoning'' is lacking . . . ' 12 The IRG was thorough and exhaustive but was not the last scienti®c panel to be heard on this issue. 13 . The ®ndings of this National Science Panel convincingly reaf®rm the existing epidemiological studies and the contentions of EQUAM and the IRG. On the issue of toxicology, the panel concluded that the preponderance of data from the animal toxicology studies`indicate that silicone implants do not alter incidence or severity of autoimmune disease . . . [T] here is no evidence that silicone breast implants precipitate novel immune responses or induce systemic in¯ammation . . . '. With respect to the immunology section, the report concluded that:
J O U R N A L O F T H E R O Y A L S O C I E T Y O F M E D I C I N E
V o l u m e 9 3 J a n u a r y 2 0 0 0 `there are no consistent data to suggest systemic in¯ammation or systemic induction of anti-silicone or autoreactive responses in women with silicone breast implants . . . Neither immune system activation nor autoreactivity could be reproducibly demonstrated in women with silicone breast implants . . . The main conclusion that can be drawn from existing studies is that women with silicone breast implants do not display a silicone-inducing systemic abnormality in the types or functions of cells of the immune system.'
Concerning epidemiology, the report found that`no association was evident between breast implants and any of the individual connective tissue diseases, all de®nite connective tissue diseases combined, or the other autoimmune/rheumatic conditions . . . There was no association between silicone gel ®lled implants and any of the de®nite connective tissue diseases (including Sjo Ègren's syndrome) or the other autoimmune/rheumatic conditions.'
The rheumatological section concluded that`many of the rheumatologic complaints reported are common in the general population and as presenting complaints in physicians' of®ces. No distinctive features relating to silicone breast implants could be identi®ed . . . '
One of the charges given the National Science Panel by Judge Pointer was to advise the court whether the panel's opinions were`subject to suf®cient genuine dispute as would permit other persons, generally quali®ed in your ®eld of expertise, to express opinions that, though contrary to yours, would likely be viewed by others in the ®eld as representing a legitimate and responsible disagreement within your profession.' On the issue of contrary opinions, the panel concluded:
It is our informed opinion that the large majority of scientists in our respective disciplines would ®nd merit in our reviews and analysis. Nevertheless, as in every ®eld of endeavor, a few individuals may ®nd disagreements with our statements. As individual scientists and as a group, we have taken no pre-determined position on the issues, nor have we designed the report to refute or enhance any point of view. On the contrary, we have allowed the existing research data to lead us to the conclusions presented. We cannot anticipate what research ®ndings may appear in the future.'
Although the report of the National Science Panel was exhaustive, the panel's role was not completed with its report. Under Rule 706, the individual panellists were subjected to deposition examination by the parties. These depositions were taken under oath and on videotape so that the testimony of the panel could be introduced nationwide at trials of cases involving silicone gel breast implants and autoimmune disease. Preliminary discovery depositions of the panellists were taken on 4±7 February 1999, in Atlanta, Georgia. Videotape trial testimonial depositions began on 20 April 1999, in Judge Pointer's courtroom in Birmingham, Alabama. The panellists testi®ed in accord with their report. It has not yet been determined whether juries will be told that these experts are neutral independent scienti®c experts appointed by the court, though under Rule 706 this is likely. In addition, the testimony of the panellists will be used in support of motions in many courts to strike the testimony of plaintiffs' junk science experts as lacking scienti®c methodology and basis under Daubert. These challenges to plaintiffs' science experts, like some of the previous challenges, will highlight the lack of sound scienti®c substantiation to the claim that silicone gel breast implants cause connective tissue disease. It is anticipated that, in several jurisdictions, the courts will disqualify`experts' who offer af®rmative disease causation opinions. With that testimony stricken, the disease claims should be dismissed for lack of valid scienti®c foundation. Some plaintiffs and their lawyers have already recognized the dif®culty in proceeding on disease-based claims.
On 21 June 1999, the National Academy of Sciences Institute of Medicine (IOM) issued its 450-page report, Safety of Silicone Breast Implants. On the issue of the relation between silicone gel breast implants and autoimmune or connective tissue disease, the committee concluded:
[T]here is insuf®cient evidence to support an association of silicone breast implants with de®ned connective tissue disease . . . The evidence supports the conclusion that there is no association, and therefore no justi®cation for the use of resources in further epidemiological exploration of such an association . . . The committee ®nds no convincing evidence for atypical connective tissue or rheumatic disease or a novel constellation of signs and symptoms in women with silicone breast implants.' 14
CONCLUSION
Will the ®ndings and conclusions of the IRG, National Science Panel, and IOM bring a speedy end to the controversy over silicone breast implants and disease? Probably not. Too many lawyers have invested too much time and money to let the matter drop. Too many plaintiffs have been needlessly frightened and had their ®nancial expectations in¯ated. The small group of hired plaintiffs' experts who have made a living out of testifying about the risks of silicone breast implants also have a vested interest in seeing that the litigation continues. Only a vigorous enforcement of the Daubert standards and the requirements of sound science by the courts will bring the controversy to an end. As Dr Marcia Angell, of The New England Journal of Medicine, stated shortly after the National Science Panel announced its ®ndings:
The implications of the report reach beyond the breast implant controversy. Courts trying technical cases have become a hotbed of junk science, and the inconsistently capricious jury verdicts that result often have more to do with the theatrical talents of the lawyers and expert witnesses than with the facts . . . As class-action lawsuits become increasingly common, Judge Pointer's appointment of a dispassionate panel of experts to evaluate the strength of the scienti®c evidence is a model more courts should follow'. 15 Whether this approach will be taken in the remaining breast implant litigation and other mass tort cases remains to be seen.
